Drug name - Trintellix

Patent Number Company Patent Title Patent Expiry Activity Alert
These patents protects the active chemical substance. Only patent owner can launch products that use this active substance.
US7144884 TAKEDA PHARMS USA Phenyl-piperazine derivatives as serotonin reuptake inhibitors
Jun, 2026

(3 years from now)

US8722684 TAKEDA PHARMS USA 1-[2-(2,4-dimethylphenylsulfanyl)-phenyl] piperazine as a compound with combined serotonin reuptake, 5-HT3 and 5-HT1A activity for the treatment of cognitive impairment
Jun, 2031

(8 years from now)

CN101636161A TAKEDA PHARMS USA 1-[2-(2,4-Dimethylphenylsulphanyl)-Phenyl]Piperazine As A Compound With Combined Serotonin Reuptake, 5-Ht3 And 5-Ht1A Activity For The Treatment Of Pain Or Residual Symptoms In Depression Relating To Sleep And Cognition
Apr, 2015

(7 years ago)

CN1561336A TAKEDA PHARMS USA Phenylpiperazine Derivatives As Serotonin Reuptake Inhibitors
Oct, 2022

(3 days ago)

CN1319958C TAKEDA PHARMS USA Phenylpiperazine Derivatives As Serotonin Reuptake Inhibitors
Oct, 2022

(3 days ago)

CN101472906B TAKEDA PHARMS USA Combination For Medicament For Treating Cognitive Impairment The Combination Of Resorbable To Serotonin, 5-Ht3 And 5-Ht1A Activity Of 1-[2-(2, 4-Dimethyl Phenyl)-Phenyl] Piperazine
Jun, 2027

(4 years from now)

CN102617513A TAKEDA PHARMS USA 1-[2-(2, 4-Dimethyl Phenyl)-Phenyl] Piperazine Of Compound As A Medicament For Treating Cognitive Impairment, Comprising Combined Activity Of Resorbable To Serotonin, 5-Ht3 And 5-Ht1A
Jun, 2027

(4 years from now)

CN102617513B TAKEDA PHARMS USA As A Medicament For Treating Cognitive Impairment, A Compound With Combined Serotonin Reuptake, 5-Ht3 And 5-Ht1A Activity Of 1 - (2 - (2, 4 - - Dimethyl Phenyl Sulfur Alkyl) - Phenyl] Piperazine
Jun, 2027

(4 years from now)

CN102614179A TAKEDA PHARMS USA Combination For Medicament For Treating Cognitive Impairment The Combination Of Resorbable To Serotonin, 5-Ht3 And 5-Ht1A Activity Of 1-[2-(2, 4-Dimethyl Phenyl)-Phenyl] Piperazine
Jun, 2027

(4 years from now)

CN101472906A TAKEDA PHARMS USA 1-[2-(2,4-Dimethylphenylsulfanyl)-Phenyl]Piperazine As A Compound With Combined Serotonin Reuptake, 5-Ht3 And 5-Ht1A Activity For The Treatment Of Cognitive Impairment
Jun, 2027

(4 years from now)

CN102614179B TAKEDA PHARMS USA As A Medicament For Treating Cognitive Impairment, A Compound Having Serotonin Reuptake Activity Of Binding, 5-Ht3 And 5-Ht1A Of 1 - [2 - (2, 4-Dimethyl Phenyl Sulfanyl) - Phenyl] Piperazine
Jun, 2027

(4 years from now)

IN227963B TAKEDA PHARMS USA Pharmaceutical Composition Comprising Phenyl-Piperazine Derivatives As Serotonin Reuptake Inhibitors
Oct, 2022

(3 days ago)

IN200800326P4 TAKEDA PHARMS USA Phenyl-Piperazine Derivatives As Serotonin Reuptake Inhibitors
Oct, 2022

(3 days ago)

IN200400910P4 TAKEDA PHARMS USA Pharmaceutical Composition Comprising Phenyl-Piperazine Derivatives As Serotonin Reuptake Inhibitors
Oct, 2022

(3 days ago)

IN257628B TAKEDA PHARMS USA Phenyl-Piperidine Derivatives As Serotonin Reuptake Inhibitors
Oct, 2022

(3 days ago)

IN200806886P4 TAKEDA PHARMS USA 1-[2-(2,4-Dimethylphenylsulfanyl)-Phenyl]Piperazine As A Compound With Combined Serotonin Reuptake,5-Ht3 And 5-Ht1A Activity For The Treatment Of Cognitive Impairment
Jun, 2027

(4 years from now)

IN322445B TAKEDA PHARMS USA A Process For The Preparation Of 1-[2- (2,4- Dimethylphenylsulfa Nyl)Phenyl] Piperazine
Jun, 2027

(4 years from now)

EP1749818A2 TAKEDA PHARMS USA Phenyl-Piperidine Derivatives As Serotonin Reuptake Inhibitors
Oct, 2022

(3 days ago)

EP1749818A3 TAKEDA PHARMS USA Phenyl-Piperazine Derivatives As Serotonin Reuptake Inhibitors
Oct, 2022

(3 days ago)

EP1749818B1 TAKEDA PHARMS USA Phenyl-Piperidine Derivatives As Serotonin Reuptake Inhibitors
Oct, 2022

(3 days ago)

EP2044043A1 TAKEDA PHARMS USA 1- Ý[- (2, 4-Dimethylphenylsulfanyl) -Phenyl]Piperazine As A Compound With Combined Serotonin Reuptake, 5-Ht3 And 5-Ht1A Activity For The Treatment Of Cognitive Impairment
Jun, 2027

(4 years from now)

EP2439201B1 TAKEDA PHARMS USA Compounds With Combined Sert, 5-Ht3 And 5-Ht1A Activity
Jun, 2027

(4 years from now)

EP2044043B2 TAKEDA PHARMS USA 1- Ý[- (2, 4-Dimethylphenylsulfanyl) -Phenyl]Piperazine Hydrobromide As A Compound With Combined Serotonin Reuptake, 5-Ht3 And 5-Ht1A Activity For The Treatment Of Cognitive Impairment
Jun, 2027

(4 years from now)

EP2044043B1 TAKEDA PHARMS USA 1- Ý[- (2, 4-Dimethylphenylsulfanyl) -Phenyl]Piperazine Hydrobromide As A Compound With Combined Serotonin Reuptake, 5-Ht3 And 5-Ht1A Activity For The Treatment Of Cognitive Impairment
Jun, 2027

(4 years from now)

EP2439201A1 TAKEDA PHARMS USA Compounds With Combined Sert, 5-Ht3 And 5-Ht1A Activity
Jun, 2027

(4 years from now)

EP1436271B3 TAKEDA PHARMS USA Phenyl-Piperazine Derivatives As Serotonin Reuptake Inhibitors
Oct, 2027

(4 years from now)

EP1436271A1 TAKEDA PHARMS USA Phenyl-Piperazine Derivatives As Serotonin Reuptake Inhibitors
Oct, 2027

(4 years from now)

EP1436271B1 TAKEDA PHARMS USA Phenyl-Piperazine Derivatives As Serotonin Reuptake Inhibitors
Oct, 2027

(4 years from now)

EP2142193B1 TAKEDA PHARMS USA 1-[2-(2,4-Dimethylphenylsulfanyl)Phenyl]Piperazine As A Compound With Combined Serotonin Reuptake, 5-Ht3 And 5-Ht1A Activity For The Treatment Of Pain Or Residual Symptoms In Depression Relating To Sleep And Cognition
Mar, 2028

(5 years from now)

EP2142193A2 TAKEDA PHARMS USA 1-[2-(2,4-Dimethylphenylsulfanyl)Phenyl]Piperazine As A Compound With Combined Serotonin Reuptake, 5-Ht3 And 5-Ht1A Activity For The Treatment Of Pain Or Residual Symptoms In Depression Relating To Sleep And Cognition
Mar, 2028

(5 years from now)

These patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc).
US9861630 TAKEDA PHARMS USA 1-[2-(2,4-dimethylphenylsulfanyl)-phenyl]piperazine as a compound with combined serotonin reuptake, 5-HT3 and 5-HT1A activity for the treatment of cognitive impairment Jun, 2027

(4 years from now)

US9125908 TAKEDA PHARMS USA 1-[2-(2,4-dimethylphenylsulfanyl)-phenyl]piperazine as a compound with combined serotonin reuptake, 5-HT3 and 5-HT1A activity for the treatment of cognitive impairment Jun, 2027

(4 years from now)

US9125910 TAKEDA PHARMS USA 1-[2-(2,4 dimethylphenylsulfanyl)-phenyl]piperazine as a compound with combined serotonin reuptake, 5-HT3 and 5-HT1A activity for the treatment of cognitive impairment Jun, 2027

(4 years from now)

US9125909 TAKEDA PHARMS USA 1-[2-(2,4 dimethylphenylsulfanyl)-phenyl]piperazine as a compound with combined serotonin reuptake, 5-HT3 and 5-HT1A activity for the treatment of cognitive impairment Jun, 2027

(4 years from now)

US9227946 TAKEDA PHARMS USA 1-[2-(2,4 dimethylphenylsulfanyl)-phenyl]piperazine as a compound with combined serotonin reuptake, 5-HT3 and 5-HT1a activity for the treatment of cognitive impairment Jun, 2027

(4 years from now)

US8969355 TAKEDA PHARMS USA 1-[2-(2,4 dimethylphenylsulfanyl)-phenyl]piperazine as a compound with combined serotonin reuptake, 5-HT3 and 5-HT1a activity for the treatment of cognitive impairment Jun, 2027

(4 years from now)

US9278096 TAKEDA PHARMS USA Therapeutic uses of compounds having combined SERT, 5-HT3 and 5-HT1A activity Mar, 2032

(9 years from now)

Drugs and Companies using VORTIOXETINE HYDROBROMIDE ingredient

Treatment: Method of treating depression or major depressive disorder; Use in the treatment of major depressive disorder to improve processing speed, an aspect of cognitive function; Use in the treatment of major depressive disorder to improve treatment emergent sexual dysfunction (tesd) induced by prior serotonin reuptake inhibitor treatment

Dosage: TABLET;ORAL

More Information on Dosage
Strength Dosage Availability
EQ 5MG BASE TABLET;ORAL Prescription
EQ 10MG BASE TABLET;ORAL Prescription
EQ 15MG BASE TABLET;ORAL Discontinued
EQ 20MG BASE TABLET;ORAL Prescription

availability in other generic markets.

Click on the highlighted region to filter.